Microbot Medical speeds up patient enrollment in pivotal clinical trial for robotic surgical system

Microbot Medical has accelerated patient enrollment in its ACCESS-PVI clinical trial for the LIBERTY Endovascular Robotic Surgical System. Currently, 80% of participants have completed follow-up, allowing the company to expect an earlier trial completion than previously planned. The company has also received final approval from the FDA for its Investigational Device Exemption (IDE) study and completed all required biocompatibility tests. It remains on track to submit its 510(k) application to the FDA by the end of 2024. ACCESS-PVI is designed to evaluate the safety and performance of the LIBERTY system in patients undergoing Peripheral Vascular Interventions. The trial's results will support the FDA submission and future commercialization efforts.